+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase



Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase



Bioorganic and Medicinal Chemistry 17(3): 1244-1250



Aldose reductase (ALR2) belongs to the aldo-keto reductase (AKR) superfamily of enzymes, is the first enzyme involved in the polyol pathway of glucose metabolism and has been linked to the pathologies associated with diabetes. Molecular modelling studies together with binding constant measurements for the four inhibitors Tolrestat, Minalrestat, quercetin and 3,5-dichlorosalicylic acid (DCL) were used to determine the type of inhibition, and correlate inhibitor potency and binding energies of the complexes with ALR2 and the homologous aldehyde reductase (ALR1), another member of the AKR superfamily. Our results show that the four inhibitors follow either uncompetitive or non-competitive inhibition pattern of substrate reduction for ALR1 and ALR2. Overall, there is correlation between the IC(50) (concentration giving 50% inhibition) values of the inhibitors for the two enzymes and the binding energies (DeltaH) of the enzyme-inhibitor complexes. Additionally, the results agree with the detailed structural information obtained by X-ray crystallography suggesting that the difference in inhibitor binding for the two enzymes is predominantly mediated by non-conserved residues. In particular, Arg312 in ALR1 (missing in ALR2) contributes favourably to the binding of DCL through an electrostatic interaction with the inhibitor's electronegative halide atom and undergoes a conformational change upon Tolrestat binding. In ALR2, Thr113 (Tyr116 in ALR1) forms electrostatic interactions with the fluorobenzyl moiety of Minalrestat and the 3- and 4-hydroxy groups on the phenyl ring of quercetin. Our modelling studies suggest that Minalrestat's binding to ALR1 is accompanied by a conformational change including the side chain of Tyr116 to achieve the selectivity for ALR1 over ALR2.

(PDF emailed within 0-6 h: $19.90)

Accession: 024412445

Download citation: RISBibTeXText

PMID: 19121944

DOI: 10.1016/j.bmc.2008.12.024


Related references

Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Bioorganic and Medicinal Chemistry 6(10): 1811-1819, 1998

Similarities and differences in the inhibition of rat lens aldose reductase and kidney aldehyde reductase by aldose reductase inhibitors. Investigative Ophthalmology & Visual Science 30(3 SUPPL): 193, 1989

Comparison of the active sites of aldose reductase and aldehyde reductase from chicken. Progress in Clinical and Biological Research 232: 275-285, 1987

Identification of pig brain aldehyde reductases with the high-Km aldehyde reductase, the low-Km aldehyde reductase and aldose reductase, carbonyl reductase, and succinic semialdehyde reductase. Journal of Neurochemistry 44(5): 1485-1493, 1985

Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. Molecular Vision 4: 19-19, 1998

Structure-activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors. Bioorganic and Medicinal Chemistry 13(8): 2809-2823, 2005

Pig muscle aldehyde reductase. Identity of pig muscle aldehyde reductase with pig lens aldose reductase and with the low Km aldehyde reductase of pig brain and pig kidney. Journal of Biological Chemistry 258(6): 3583-3586, 1983

Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites. Cellular and Molecular Life Sciences 64(15): 1970-1978, 2007

Inhibition of aldehyde reductase by aldose reductase inhibitors. Biochemical Pharmacology 40(5): 1033-1042, 1990

Aldose and aldehyde reductases: Correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site. Proteins 41(3): 407-414, November 15, 2000

Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features. Journal of Molecular Biology 379(5): 991-1016, 2008

Inactivation of carbonyl reductase from human brain by phenylglyoxal and 2,3-butanedione: a comparison with aldehyde reductase and aldose reductase. Biochimica et Biophysica Acta 916(2): 185-192, 1987

Human aldehyde reductase and aldose reductase show iso cortico steroid reductase activity. Experientia 38(6): 734, 1982

X-ray and molecular modelling studies of new potential aldose reductase inhibitors. Acta Crystallographica Section A Foundations of Crystallography 52(A1): C253-C253, 1996

Monkey 3-deoxyglucosone reductase: tissue distribution and purification of three multiple forms of the kidney enzyme that are identical with dihydrodiol dehydrogenase, aldehyde reductase, and aldose reductase. Archives of Biochemistry and Biophysics 307(2): 286-294, 1993